Numab Therapeutics AG

ROR1-Targeted Therapies Show Promise in Lymphoma and Solid Tumors

5 months ago

• Zilovertamab vedotin combined with R-CHP achieved a 100% complete response rate in untreated diffuse large B-cell lymphoma patients in a Phase 2 trial. • CS5001 demonstrated an overall objective response rate of 48.4% across all dose levels in patients with advanced lymphomas, showing activity in both solid tumors and lymphomas. • ROR1 is a promising target due to its overexpression in various cancers and its role in tumor growth and metastasis, making it a focus for novel therapies. • Clinical trials are underway for multiple ROR1-targeting therapies, including ADCs, bispecific antibodies, and CAR-T cell therapy, offering new options for cancer patients.

Roflumilast Cream Shows High Efficacy in Treating Atopic Dermatitis in Adults and Children

6 months ago

• Roflumilast cream 0.15% demonstrated significantly higher efficacy than the vehicle in achieving a validated IGA-AD score of 0/1 in patients with atopic dermatitis. • The study found that over 95% of patients treated with roflumilast cream reported no signs of application site irritation, highlighting its tolerability. • Roflumilast significantly improved EASI 75 scores compared to the vehicle, indicating a substantial reduction in eczema severity among treated patients. • This once-daily, nonsteroidal cream addresses key unmet needs in atopic dermatitis treatment, potentially improving patient adherence and outcomes.

Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline

a year ago

• Johnson & Johnson will acquire Yellow Jersey Therapeutics for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis. • NM26 targets both IL-4Rα and IL-31, addressing inflammation and itch, potentially offering advantages over existing treatments like Dupixent. • The acquisition aligns with J&J's strategy to expand its immunology portfolio with differentiated bispecifics, following recent deals in oncology and immunology. • Numab Therapeutics' MATCH™ technology platform, used to develop NM26, is validated by this deal, highlighting its potential for creating novel multi-specific antibodies.